Young-Ho Lee
Director Ejecutivo en Immunique Co. Ltd. .
Cargos activos de Young-Ho Lee
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| Hanyang University | Corporate Officer/Principal | - | - |
Immunique Co. Ltd.
 Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Director Ejecutivo | - | - |
Historial de carrera de Young-Ho Lee
Antiguos cargos conocidos de Young-Ho Lee.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| NANOENTEK, INC. | Director/Miembro de la Junta | 24/03/2022 | 08/09/2023 |
| Independent Dir/Board Member | 24/03/2022 | 08/09/2023 |
Formación de Young-Ho Lee.
| Hanyang University | Doctorate Degree |
Estadísticas
Internacional
| Corea del Sur | 4 |
Operativa
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 2 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| NANOENTEK, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Immunique Co. Ltd.
Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Commercial Services |
- Bolsa de valores
- Insiders
- Young-Ho Lee
- Experiencia